利妥昔单抗联合CHOP综合治疗B细胞性非霍奇金淋巴瘤的临床研究  

Efficacy of Rituximab Combined with CHOP for B Cell Non-Hodgkin's Lymphoma

作　　者：谢春英[1] 刘安文[1] 李凌[1] 王顺金[1] 

机构地区：[1]南昌大学第二附属医院肿瘤科,南昌市330006

出　　处：《中国肿瘤临床》2009年第24期1398-1400,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:评价利妥昔单抗与CHOP联合治疗B细胞性非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)的临床效果及不良反应。方法:用同期对照的前瞻性研究方法,将60例B细胞性NHL患者分为研究组(利妥昔单抗组)和对照组,研究组30例用CHOP方案联合利妥昔单抗治疗;对照组30例单用CHOP方案。CHOP方案:环磷酰胺600mg/m^2,静脉注射,dl;吡喃阿霉素或阿霉素50mg/m^2,静脉注射,d1;长春新碱1.4mg/m^2,静脉注射,dl;强的松I00mg,口服,dl～d5,每21天为1个周期。RCHOP方案:美罗华375mg/m^2,静脉滴注,每1个周期第1天(d1);第3天开始CHOP方案,每21天为1个周期。全部60例患者完成3～6个周期化疗后进行疗效评价。结果:利妥昔单抗组完全缓解率(CR)达66.7%(20/30),总有效率90.0%(27/30);对照组CR为40.0%(12/30),总有效率为56.7%(17/30),两组疗效差异有统计学意义,P<0.05。结论:利妥昔单抗联合CHOP方案治疗CD20阳性的B细胞性NHL的疗效显著,不良反应与单纯化疗相似,可作为该病目前的首选方案。Objective： To evaluate the therapeutic effects of Rituximab combined with CHOP on B cell non-Hodgkin＇s lymphoma. Methods： A prospective study with concurrent control group was carried out. A total of 60 cases of B cell non-Hodgkin＇s lympoma were divided into 2 groups. The 30 cases in the research group received Rituximab combined with CHOP regimen. The 30 cases in the control group were treated with CHOP regimen alone. CHOP regimen （Cyclophospham 600mg/m2 Ⅳ, Vincristine 1.4mg/m2 Ⅳ, and Adriamycin piarubicin 50mg/m2 Ⅳ） was administered on the first day of chemotherapy course. Prednisone 100mg/m2 was administered orally from the first day to the fifth day. The cycle was repeated every 21 days and the patients received at least 3-6 cycles of chemotherapy. The therapeutic effect was assessed. Results： The com- plete remission （CR） rate and total response rate were 66.7% （20/30） and 90.0% （27/30） in the research group and 39.97% （12/30） and 56.7% （17/30） in the control group. The therapeutic differences between the two groups showed a statistical significance （P〈0.05）. Conclusion： Compared with CHOP regimen chemotherapy, Rituximab combined with CHOP regimen shows better therapeutic effect. The side effects in the research group are similar to those in the control group. Rituximab combined with CHOP regimen can be the first choice in the treatment for B cell non-Hodgkin＇s lymphoma.

关 键 词：非霍奇金淋巴瘤 利妥昔单抗 CHOP方案 临床研究 

分 类 号：R733.1[医药卫生—肿瘤] R733.4[医药卫生—临床医学]